Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 10, Octobre 2016
Page(s) 861 - 866
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163210019
Publié en ligne 19 octobre 2016
  1. Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 ; 360 : 1903–1913. [CrossRef] [PubMed]
  2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009 ; 338 : b1665. [CrossRef] [PubMed]
  3. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987 ; 1 : 581–584. [CrossRef] [PubMed]
  4. Chalmers J. Is a blood pressure target of < 130/80 mmHg still appropriate for high-risk patients? Circulation 2011 ; 124 : 1700–1702. [CrossRef] [PubMed]
  5. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. INVEST revisited: review of findings from the international verapamil SR-trandolapril study. Expert Rev Cardiovasc Ther 2009 ; 7 : 1329–1340. [CrossRef] [PubMed]
  6. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press 2015 ; 1–10. [CrossRef] [PubMed]
  7. Turnbull F, Neal B, Algert C, et al. Blood pressure lowering treatment trialists’ collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 ; 165 : 1410–1419. [CrossRef] [PubMed]
  8. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1575–1585. [CrossRef] [PubMed]
  9. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 2010 ; 122 : 847–849. [CrossRef] [PubMed]
  10. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013 ; 382 : 507–515. [CrossRef] [PubMed]
  11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033–1041. [CrossRef] [PubMed]
  12. Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med 2012 ; 9 : e1001293. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  13. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2013 ; 31 : 1281–1357. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  14. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 ; 373 : 2103–2116. [CrossRef] [PubMed]
  15. MacMahon S, Neal B, Rodgers A. Hypertension: time to move on. Lancet 2005 ; 365 : 1108–1109. [CrossRef] [PubMed]
  16. Chobanian AV. Time to reassess blood-pressure goals. N Engl J Med 2015 ; 373 : 2093–2095. [CrossRef] [PubMed]
  17. Drazen JM, Morrissey S, Campion EW, et al. A SPRINT to the finish. N Engl J Med 2015 ; 373 : 2174–2175. [CrossRef] [PubMed]
  18. Perkovic V, Rodgers A. Redefining blood-pressure targets–SPRINT starts the marathon. N Engl J Med 2015 ; 373 : 2175–2178. [CrossRef] [PubMed]
  19. Jones DW, Weatherly L, Hall JE. SPRINT: What remains unanswered and where do we go from here? Hypertension 2016 ; 67 : 261–262.
  20. Cushman WC, Whelton PK, Fine LJ, et al. SPRINT Trial results: Latest news in hypertension management. Hypertension 2016 ; 67 : 263–265.
  21. Esler M. SPRINT, or false start, toward a lower universal treated blood pressure target in hypertension. Hypertension 2016 ; 67 : 266–267.
  22. Touyz RM, Dominiczak AF. Successes of SPRINT, but still some hurdles to cross. Hypertension 2016 ; 67 : 268–269. [CrossRef]
  23. Kjeldsen SE, Oparil S, Narkiewicz K, et al. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press 2016 ; 25 : 1–3. [CrossRef] [PubMed]
  24. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 ; 311 : 507–520. [CrossRef] [PubMed]
  25. Yusuf S, Sleight P, Pogue J, et al. The heart outcomes prevention evaluation (HOPE) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 ; 342 : 145–153. [CrossRef] [PubMed]
  26. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009 ; 30 : 1385–1394. [CrossRef] [PubMed]
  27. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial: lipid lowering arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003 ; 361 : 1149–1158. [CrossRef] [PubMed]
  28. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 ; 355 : 549–559. [CrossRef] [PubMed]
  29. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 ; 351 : 1755–1762.
  30. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010 ; 303 : 1180–1187. [CrossRef] [PubMed]
  31. Bress AP, Tanner RM, Hess R, et al. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol 2016 ; 67 : 463–472. [CrossRef] [PubMed]
  32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999 ; 341 : 709–717. [CrossRef] [PubMed]
  33. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Lancet 1990 ; 335 : 827–838. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.